Article Sidebar

Submitted
May 3, 2021
Published
May 3, 2021
Download
PDF
Statistic
Read Counter : 66 Download : 28

Main Article Content

Abstract

Aim


To study the effect of Escitalopram on biomarkers of depression in patients of   multidrug resistant tuberculosis (MDR-TB) suffering with depression.


Material and Methods


Total 35 diagnosed MDR TB patients were selected from Tuberculosis and Respiratory diseases department complaining depression symptoms in their MDR TB treatment follow up. These patients were referred to Psychiatry OPD for diagnosis of depression.


Hamilton Depression Rating Scale (HDRS) score was computed to categorize depression as mild, moderate and severe depression. 24 MDR TB patients diagnosed with mild to moderate depression were enrolled.Escitalopram (10mg) were administered to enrolled patients already taken Standard MDR-tuberculosis treatment. Follow up was done at day 30 and day 120.


Depression improvement assessed by HDRS score and biomarker alterations assessed by serum lipid profile- Serum cholesterol, Triglyceride (Tg), Low density lipoprotein (LDL), High density lipoprotein (HDL) and very low density lipoprotein cholesterol (VLDL). Data were compiled and analyzed using SPSS 20.0 and paired t – test.


Result


Total 19 patients had completed the study. 3 and 2 patients were lost in follow up at day 30 and 120 respectively.  Baseline HDRS score (13.53 ± 2.58) were decreased at day 30 (6.11 ± 1.28) and Day 120 (3.05 ± 0.91) which were significant (p˂0.001). Lipid profile parameters were not increased significantly at any follow up.


Conclusion


Escitalopram drug therapy improved depression symptoms without significantly affecting the biomarkers for depression (lipid profile).

Keywords

Escitalopram Serum cholesterol Triglyceride Low density lipoprotein High density lipoprotein

Article Details

How to Cite
Vijay Kumar Singh, Virendra Kushwaha, Pooja Agrawal, Rakesh Kumar Dixit, Amit Kumar, Dhananjay Chaudhari, Anand Kumar, & Mahesh Chandra Bindal. (2021). The effect of escitalopram on biomarkers of depression in patients of multidrug resistant tuberculosis (MDR-TB) suffering with depression. International Journal of Research in Pharmacology & Pharmacotherapeutics, 6(4), 427-433. https://doi.org/10.61096/ijrpp.v6.iss4.2017.427-433
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. [1]. World Health Organization. WHO Global tuberculosis report, 2016, 15- 16. [Accessed 2017] Available at: www.who.int/tb /publications /global_report/en.
  2. [2]. TB India 2017, 9 [Accessed 2017] Available at tbcindia.gov.in/index1.php lang=1 &level=2&sublinkid = 4728&lid=3275.
  3. [3]. Pachi A, Bratis D, Moussas G, Tselebis A. Psychiatric Morbidity and Other Factors Affecting treatment adherence in pulmonary tuberculosis patients. Tuber Res Treat 2013, 2013, 489865
  4. [4]. Lykouras E, Ioannidis H, Voulgaris D. Depression in general hospital patients: preliminary results,Archives of Hellenic Medicine 4, 1987, 287–89.
  5. [5]. Vega P, Sweetland A, Acha J, Castillo H, Guerra D, Smith FMC, et al. Psychiatric issues in the management of patients with multidrug resistant tuberculosis. Int. J Tuberc Lung Dis 8(6), 2004, 749-59
  6. [6]. Companion Handbook to the WHO Guidelines for The Programmatic Management of Drug-Resistant Tuberculosis 2017, 106 [Accessed 2017]. Available at: www.who.int/tb/publications/pmdt_companion handbook/en.
  7. [7]. Sanchez C, Reines ES, Stuart A, Montgomery A. comparative review of escitalopram, paroxetine, and sertraline: are they all alike? IntClinPsychopharmacol. 29(4), 2014, 185–196
  8. [8]. Kirino E. Escitalopram for the management of major depressive disorder: a review of its efficacy, safety, and patient acceptability. Patient Prefer Adherence. 6, 2012, 853–61.
  9. [9]. Mössner R, Mikova O, Koutsilieri E, Saoud M, Ehlis AC, Müller N, et al. Consensus paper of the WFSBP Task Force on Biological Markers: Biological markers in depression. World J Biol Psychiatry 8(3), 2007, 141-74
  10. [10]. Parekh A, Smeeth D, Milner Y, Thuret S. The Role of Lipid Biomarkers in Major Depression Healthcare 2017, 5, 5.
  11. [11]. Terao T, Iwata N, Kanazawa K, Takano T, Takahashi N, Hayashi T, et al. Low serum cholesterol levels and depressive state in human dock visitors. ActaPsychiatr. Scand. 101, 2000, 231–34.
  12. [12]. Berardis D, Marini S, Piersanti M, Cavuto M, Perna G, Valchera A, et al. The Relationships between Cholesterol and Suicide: An Update. ISRN Psychiatry 2012, 2012, 387901
  13. [13]. Deisenhammer EA, Kramer K R, Liensberger D, Kemmler G, Hinterhuber H. No evidence for an association between serum cholesterol and the course of depression and suicidality. Psychiatry Res 121, 2004, 25361
  14. [14]. Arain A.A., Memon A.R., Kazi H, MashoriB.A. Reduction of Serum Lipid Profile by Escitalopram in Depressive Patients: A Cardio Protective Aspect of SSRI Use. J Cardiol&CardiovascTher Research Article.April 4(4), 2017.
  15. [15]. Eker.O, Ozsoy S, Eker B, Doğan H .Metabolic Effects of Antidepressant Treatment. Arch Neuropsychia 54, 2017, 49-56
  16. [16]. Beyazyüz M, Albayrak Y, Eğilmez O B, Albayrak N, Beyazyüz E. Relationship between SSRIs and Metabolic Syndrome Abnormalities in Patients with Generalized Anxiety Disorder: A Prospective Study. PsychiaInvestig 10(2), 2013, 148–54.